+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
37.3000
.6793
-.6975
72.7791
3.2796
8.2193
Low
63.5004
4.1856
Yes
No
No
No
No
No
1.5
Yes
No
Yes
Yes
Sodium dichloroacetate (DCA), CAS number 2156-56-1, is a simple organic small molecule compound with significant biological activity. As an inhibitor of pyruvate dehydrogenase kinase (PDK), DCA can activate the pyruvate dehydrogenase complex (PDC), promoting mitochondrial oxidation processes involved in intracellular energy metabolism. In recent years, DCA has become a research hotspot in the field of tumor metabolic therapy due to its potential role in tumor metabolism regulation. By regulating the metabolic reprogramming of cancer cells, it inhibits lactate production and induces reactive oxygen species (ROS), thereby suppressing tumor cell proliferation and inducing apoptosis, demonstrating good anti-tumor potential. This paper will systematically review the chemical structure and physicochemical properties, sources and extraction, pharmacological activity, mechanism of action and molecular targets, druggability evaluation, pharmacokinetic characteristics, and clinical application prospects of sodium dichloroacetate, aiming to provide scientific evidence for further research and development of this compound.
Sodium dichloroacetate has the chemical formula C2HCl2NaO2 and a molecular weight of 128.9420. Its molecular structure contains a dichloro-substituted acetate group, and sodium ions exist in the form of salts. The compound has a LogP value of 0.6793, indicating moderate lipophilicity and the ability to maintain a certain balance between the aqueous and lipid phases. The polar surface area (TPSA) was 37.3 Ų, indicating that its molecules have certain polarity, which is beneficial for water solubility and penetration of biofilms. It has relatively high water solubility, about 72.7791 mg/mL, which is beneficial for oral drug absorption. The blood-brain barrier has a lower permeability to reduce the risk of central nervous system side effects. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames mutagenic test scored 1.5, indicating low genotoxicity and good safety.
The simplicity of its chemical structure and excellent physicochemical properties give sodium dichloroacetate certain advantages in drug development, especially in the design and distribution of oral formulations.
Sodium dichloroacetate, as a simple organic salt, has traditionally not been extracted directly from plants, but is prepared through chemical synthesis. Its chemical synthesis typically involves the reaction of dichloroacetic acid with sodium hydroxide to form a sodium salt. Nevertheless, natural precursors and related organic acids of dichloroacetic acid are widely present in various plant and microbial metabolites, providing a foundation for research into its biosynthetic pathways.
In recent years, with the development of natural product pharmacology, some studies have attempted to screen organic acids and their derivatives with similar structures from plant metabolites, exploring their structure-activity relationships (SAR) with sodium dichloroacetate. However, sodium dichloroacetate itself is not a typical plant-derived natural product; its application relies more on high-purity chemical synthesis processes.
The pharmacological activity of sodium dichloroacetate mainly lies in its ability to regulate cellular energy metabolism, especially its role in tumor cell metabolic reprogramming. As a PDK inhibitor, DCA removes the phosphorylation inhibition of PDH, restores its activity, promotes the entry of pyruvate into mitochondria for oxidative metabolism, reduces lactate production, and reverses the Warburg effect in cancer cells (i.e., preference for anaerobic glycolysis). This metabolic shift not only inhibits tumor cell proliferation but also induces apoptosis by increasing mitochondrial reactive oxygen species (ROS) levels.
Additionally, DCA can inhibit Na+-K+-2Cl cotransporter (NKCC), affecting intracellular ion balance and volume regulation, further interfering with tumor cell physiological functions. Multiple in vitro and in vivo experiments have shown that DCA has significant anti-proliferative and pro-apoptotic effects on various tumor cell lines, including lung cancer, breast cancer, glioma, etc.
In the field of non-tumor diseases, DCA also shows potential in modulating mitochondrial function and metabolic disorders, such as lactic acidosis and mitochondrial diseases, but its core research and applications remain focused on tumor metabolic therapy.
The main mechanism of action of sodium dichloroacetate is based on its inhibition of pyruvate dehydrogenase kinase (PDK). PDK phosphorylates the E1α subunit of PDC, inhibiting its activity and blocking the oxidative metabolic pathway of pyruvate entering mitochondria. DCA activates PDC by blocking this phosphorylation process, promoting the transport of pyruvate into mitochondria, enhancing oxidative phosphorylation, inhibiting lactate production, and correcting metabolic abnormalities in cancer cells.
Regarding molecular targets, DCA affects several key proteins related to tumor growth and survival:
These multi-target effects give DCA broad application potential in tumor treatment, especially in combination therapies, enhancing anti-tumor effects through synergistic effects.
The druggability parameters of sodium dichloroacetate indicate that it has promising potential for drug development. Moderate molecular weight, high water solubility, and easy to absorb orally. The LogP value is moderate, combining hydrophilicity and lipophilicity, facilitating drug distribution in the body. Its relatively low polar surface area helps penetrate cell membranes.
The blood-brain barrier has low penetration capacity, reducing the risk of central nervous system toxicity. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. Ames test results showed low genotoxicity and good safety.
Pharmacokinetics, DCA is rapidly absorbed orally, with a plasma half-life of about 1-2 hours. It is mainly metabolized by the liver, with metabolites excreted primarily by the kidneys. Its pharmacokinetic profile supports routine oral administration but also suggests dose adjustments to avoid potential toxic side effects.
As a metabolic regulator, sodium dichloroacetate demonstrates unique advantages in the field of tumor treatment. By correcting metabolic abnormalities in cancer cells and inhibiting tumor growth and metastasis, it has become an emerging direction in tumor metabolic therapy. Multiple preclinical studies and early clinical trials have confirmed its potential efficacy in various solid tumors such as gliomas, lung cancer, and breast cancer.
In the future, DCA is expected to serve as a monotherapy or in combination with chemotherapy, radiotherapy, and immunotherapy as adjuncts, improving overall cancer treatment outcomes. Its low cost and convenient oral consumption also make it suitable for widespread adoption.
However, the clinical application of DCA still faces some challenges, such as dose optimization, long-term safety assessment, and the establishment of individualized treatment regimens. Furthermore, in-depth analysis of its molecular mechanisms and the search for biomarkers to predict efficacy will help improve its clinical translation rate.
Future research should focus on the synergistic mechanisms of DCA with other antitumor drugs, optimize dosing regimens, expand indications, and strengthen exploration of their potential applications in non-tumor metabolic diseases.
Sodium dichloroacetate, as a metabolic regulator with a well-defined mechanism of action, holds an important position in the fields of natural product pharmacology and tumor metabolic therapy. By inhibiting PDK, activating PDH, correcting abnormal cancer cell metabolism, inhibiting tumor proliferation, and inducing apoptosis, it demonstrates good antitumor activity. Combined with its excellent physicochemical properties and druggability, DCA has broad clinical application prospects.
Although more clinical data are still needed to support its safety and efficacy, sodium dichloroacetate undoubtedly offers new ideas and strategies for tumor metabolic therapy. In the future, as molecular target research deepens and drug development technology advances, DCA is expected to become an important drug in the field of cancer treatment, bringing new hope for treatment to patients.
Shenshuai
Wenjing
Hedandan
